progression, defined as an increase in EDSS confirmed in the subsequent months (typically 3 or 6), has been the endpoint used to assess the effect of treatments on disability accumulation in all multiple sclerosis (MS) phase III clinical trials, both in relapsing-remitting (RR) and in progressive MS. In trials assessing highly effective drugs, the concept of confirmed EDSS improvement (defined as a decrease in EDSS confirmed in the subsequent months) was recently introduced. 3 Current clinical trials reported an unexpectedly low rate of EDSS progression events. In the CONCERTO study, for example, the EDSS progression rate in placebo patients was around 11% over 2 years 4 ; in the pooled RADIANCE and SUNBEAM studies, the 15-month rate of events in the IFNbeta-1a arms was 4.2%. 5, 6 A recent meta-analysis showed that EDSS disease progression in placebo arms of clinical trials exhibits similar decline over time as the annualized relapse rate. 7 It is therefore recognized that modern trials include patients with less active disease than past trials, and that more rigorous methods of outcome assessments may play a role in decreasing the detection of spurious events (eg, adjudication committees for relapses). Modern trials, conversely, tend to include populations from areas of the world not included in the past (mainly Eastern Europe and India). With this background, taking advantage of data from a pooled dataset of 3 randomized controlled trials (RCTs) in RRMS with the same inclusion criteria, we investigated whether there are differences in the proportion of patients with progression or improvement events (defined on the EDSS) and on other more easily quantifiable clinical endpoints, such as the Timed 25-Foot Walk (T25FW) 8 and the Multiple Sclerosis Functional Composite (MSFC), 9, 10 related to the region of the world where the trial was conducted.
Patients and Methods

Patients
This is a post hoc analysis of 3 RCTs, the ALLEGRO, BRAVO, and CONCERTO studies (ClinicalTrials.gov identifiers: NCT00509145, NCT00605215, and NCT01707992, respectively). The study design and inclusion/exclusion criteria were the same for the 3 trials and have been described elsewhere. 4, 11, 12 The ethics committees and institutional review boards of all participating centers approved the study protocols. All participants provided written informed consent. 11, 12 Briefly, eligibility criteria included age of 18 to 55 years, diagnosis of RRMS (revised McDonald criteria 13 , and EDSS scores of 0 to 5.5. Patients must have had at least 1 relapse in the previous 12 months, 2 relapses in the previous 24 months, or 1 relapse in the previous 12 to 24 months plus 1 gadolinium-enhancing lesion in the previous 12 months.
For the purpose of this study, we analyzed only patients included in the placebo arms of the pooled studies. Patients were grouped according to the geographical region of enrollment, as reported in the Table. Outcomes We analyzed disability progression/improvement, defined as a 1.0-point increase/decrease in EDSS score if baseline score was between 0 and 5.0, or a 0.5-point increase/ decrease if baseline score was 5.5, sustained for 3 months 3, 4, 11, 12 ; and the Timed 25-Foot Walk (T25FW) progression, defined as the increase of at least 20% from baseline, sustained for 3 months. 14 We also analyzed the MSFC 9,10 change over 2 years in the subgroup of trials where this endpoint was collected (ALLEGRO and BRAVO).
11,12
Statistical Methods
Comparisons between patients were run by the nonparametric Kruskal-Wallis test and the chi-square test. Kaplan-Meier survival curves and Cox models adjusting for baseline covariates and study group were used to display and compare progression and improvement risk among groups. MSFC change over 2 years was compared among groups by an analysis of variance model adjusted for baseline characteristics and study group.
Results
A total of 1,746 RRMS patients treated with placebo were included in the analysis, and their baseline characteristics, according to the 3 geographical regions, are reported in the Table; 291 (17%) were enrolled in Western European centers, 145 (8%) in the USA/Canada, and 1,310 (75%) in Eastern Europe.
Patients enrolled in the placebo arms in Eastern European countries were younger; with a more recent disease onset and shorter disease duration; with higher EDSS score; and higher MRI lesion volumes than placebotreated patients from Western Europe or the USA/Canada (see Table) .
At univariate analysis, the actuarial proportion of patients with 3-month confirmed EDSS progression was significantly heterogeneous (p < 0.0001) among the 3 geographical regions; a higher 2-year cumulative probability of EDSS progression was observed for patients enrolled in the USA/Canada (21.4%), followed by those enrolled in Western Europe (13.1%), whereas the lowest risk was observed for those enrolled in Eastern Europe (10.8%; Fig  1A) . The same was true for the actuarial proportion of patients with 3-month confirmed EDSS improvement (p = 0.0002); a higher 2-year cumulative probability of EDSS improvement was observed for patients enrolled in the USA/Canada (13.4%), followed by those enrolled in Western Europe (12%), whereas the lowest proportion was observed for those enrolled in Eastern Europe (6.8%; see Fig 1B) .
Additional details on heterogeneity across the countries within Eastern Europe are reported in the Supplementary Material.
Because there were differences among the 3 regions in baseline characteristics (see Table) , we ran a multivariate model to check whether the heterogeneity in the actuarial proportion of patients with EDSS progression and improvement could be explained by differences of the baseline variables. However, when adjusting for all the baseline variables, the EDSS progression risk differences among the geographical regions were maintained (p < 0.0001); with the Eastern Europe group as a reference, the hazard ratios (HRs) for Western Europe and USA/Canada patients, adjusted for the baseline characteristics, were 1.7 (95% confidence interval [CI] = 1.2-2.5, p = 0.006) and 2.3 (95% CI = 1.5-3.7, p = 0.0003), respectively. The heterogeneity was maintained also for the proportion of patients with EDSS improvement (p = 0.004); with the Eastern Europe group as a reference, the HRs for Western Europe and USA/Canada patients, adjusted for the baseline characteristics, were 1.9 (95% CI = 1.2-3.1, p = 0.01) and 1.6 (95% CI = 0.9-2.8, p = 0.12), respectively.
Conversely, there were no detectable differences in T25FW progression among patients enrolled in the 3 geographical regions (Eastern Europe = 16.9%, Western Europe = 13.4%, USA/Canada = 13.9%); adjusting for the baseline characteristics and taking Eastern Europe as reference, the HR for Western Europe was 0.9 (95% CI = 0.6-1.5, p = 0.73) and it was 0.8 (95% CI = 0.4-1.5, p = 0.51) for the USA/Canada (Fig 2A) . Also the MSFC change, assessed in 2 trials (n = 826), was not significantly different among the geographical regions (see Fig 2B) ; the mean MSFC change was +0.002 (95% CI = −0.031 to 0.034) in Eastern Europe, it was −0.030 (95% CI = −0.082 to 0.023) in Western Europe, and it was +0.001 (95% CI = −0.063 to 0.065) in the USA/Canada (p = 0.66); the comparison was not affected by baseline adjustment.
All details of the regression models are reported in the Supplementary Material.
Discussion
This study run on the placebo arms of 3 large RCTs revealed a high heterogeneity in the proportion of patients with both an EDSS progression and an EDSS improvement according to the geographic area of enrollment (Western Europe vs Eastern Europe vs the USA/Canada); this heterogeneity cannot be explained by differences of baseline characteristics. Notably, the differences in EDSS progression/improvement among geographical regions are much higher than those usually observed due to treatment effects on this outcome. Moreover, disability progression defined on more "objective" and quantitative measures, such as the T25FW and the MSFC, did not differ across regions. The USA/Canada and Western Europe had a higher EDSS progression risk than Eastern Europe and, at the same time, they had also a higher probability of EDSS improvement, suggesting a generalized higher proportion of EDSS change detection (in both directions) in such regions. This observation supports the hypothesis of a heterogeneity in the methods and criteria used for EDSS progression/improvement assessment, indicating a higher sensitivity in detecting changes in the USA/Canada and Western Europe versus Eastern Europe. It is difficult to speculate about the reasons for these differences. A higher sensitivity can be motivated by a higher confidence in EDSS assessment or in longer times dedicated to the clinical visits in Western Europe and the USA/Canada. This observation has implications for planning clinical trials and for the interpretation of results of observational studies. Many recent clinical trials have been planned to recruit patients mostly in Eastern Europe. This choice was motivated by an expected higher recruitment rate in such regions due to the lower number of competitive trials and to limited access to highly expensive drugs in such geographical regions. This analysis reveals that the enrollment in Eastern Europe can in large part account for the decreased number of progression events detected in RRMS in many recent trials, [4] [5] [6] which made them underpowered to detect any treatment effect on EDSS progression. The implications of such heterogeneities are even more relevant when evaluating the results of observational studies of comparative effectiveness of different drugs, especially when run on large multinational registries. Heterogeneous EDSS assessment criteria in different geographical regions can bias the comparisons of drug effectiveness when the evaluated drugs are not evenly balanced across countries. As an example of such a situation, in the MSBase study comparing alemtuzumab to other drugs 15 the alemtuzumab cohort was entirely enrolled in the United Kingdom, whereas no other MSBase center enrolling patients in the comparators arms was in the United Kingdom. The results of this study, reflecting a large dataset of >1,700 patients from 3 clinical trials, enrolled according to the same inclusion criteria and followed for 2 years under placebo, call for harmonization procedures for MS patients' clinical assessment. Large efforts have been devoted to defining composite outcomes to improve the clinical assessment of MS patients 9, 16 ; the MSFC, incorporating 3 functional measures, reflecting cognition, ambulation, and upper limb function, is an example of such an effort. However, these attempts to create new measures were mainly focused on increasing the sensitivity of the outcome and its ability to better assess multiple disease aspects. Despite these efforts, EDSS progression remains the most commonly used outcome for disability assessment both in clinical trials and in clinical practice. This study shows that not only sensitivity of EDSS progression must be improved, but also, and perhaps more importantly, the objectivity of its measurement. At a time when disease progression and disability represent the targets for future interventions in MS, establishment of more quantitative and objective outcome measures remains a key priority for researchers in the field.
